A Phase 3, Multi-Center, Placebo- and Active-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Pemafibrate (Primary) ; Fenofibrate
- Indications Hypertriglyceridaemia; Low HDL cholesterol
- Focus Registrational; Therapeutic Use
- Sponsors Kowa
- 26 Sep 2021 Status changed from not yet recruiting to recruiting.
- 18 Aug 2021 New trial record